Citations

Clear

148 citation(s) found for "Stock, W".

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia
Muffly, Lori , Yin, Jun , Wall, Anna, Quiroz, Elisa , Advani, Anjali S. , Luger, Selina M. , Tallman, Martin S. , Litzow, Mark R. , Appelbaum, Frederick R. , Keegan, Theresa H.M. , Jacobson, Sawyer , Advani, Anjali S , Litzow, Mark R. , Erba, Harry Paul , Larson, Richard A , Muffly, Lori , Foster, Matthew C , Larson, Richard A. , Stock, Wendy

Mayo Clinic

Blood Advances | July 15, 2022 | Volume: 6 | Issue: 14 | Pages: 4085-4092

10.1182/bloodadvances.2022007197 | PMID 35838753 Get It

Abstract In this secondary analysis of Hispanic adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated on Cancer and Leukemia Group B (CALGB) 10403, we evaluated outcomes and geographic enrollment patterns relative to US population data. We used demographic, clinical, and survival data on AYAs enrolled on CALGB 10403 (N = 295, 2007-2012). Surveillance, Epidemiology, and End Results registries provided overall survival (OS) for US AYA ALL by ethnicity/race. North American Association of Cancer Registries provided AYA ALL incidence overall and proportion among Hispanics by US state. Of AYAs enrolled on CALGB 10403, 263 (89%) reported ethnicity/race: 45 (17%) Hispanic, 172 (65%) non-Hispanic White (NHW), 25 (10%) non-Hispanic Black (NHB), and 21 (8%) other. Compared with NHWs, Hispanic and NHB patients had lower household income, and Hispanic patients were more likely to harbor high-risk CRLF2 aberrations. Relative to US estimates, where Hispanic patients represented 46% of newly diagnosed AYA ALL patients and experienced inferior OS compared with NHW (P < .001), Hispanic AYAs on CALGB 10403 did as well as NHW patients (3 year OS, 75% vs 74%; P = NS). Hispanic patients also had higher rates of protocol completion (P = .05). Enrollments on CALGB 10403 differed relative to the distribution of Hispanic AYA ALL in the United States: enrollment was highest in the Midwest; t and only 15% of enrollees were from states with a high proportion of Hispanic AYA ALL patients. In summary, Hispanic patients treated on CALGB 10403 did as well as NHWs and better than population estimates. Geographical misalignment between trial sites and disease epidemiology may partially explain the lower-than-expected enrollment of Hispanic AYA ALL patients.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Arber, Daniel A. , Hasserjian, Robert P. , Borowitz, Michael J., Kvasnicka, Hans Michael , Wang, Sa A. , Bagg, Adam , Barbui, Tiziano , Branford, Susan , Bueso‐Ramos, Carlos E. , Cortes, Jörge E. , Cin, Paola Dal , Dombret, Hervé , Duncavage, Eric J., Ebert, Benjamin L. , Estey, Elihu H. , Foucar, Kathryn , Gangat, Naseema , Gökbuget, Nicola , Hellström‐Lindberg, Eva , Beau, Michelle M. Le , Löwenberg, Bob , Malcovati, Luca , Odenike, Olatoyosi , Papaemmanuil, Elli , Porkka, Kimmo , Radich, Jerald P. , Reiter, Andreas , Rudelius, Martina , Schiffer, Charles A. , Sierra, Jorge , Stone, Richard M. , Tallman, Martin S. , Thiele, Jürgen, Tzankov, Alexandar , Wei, Andrew H. , Weinberg, Olga K. , Wierzbowska, Agnieszka , Cazzola, Mario , Tefferi, Ayalew , Hasserjian, Robert P , Kvasnicka, Hans-Michael , Barbui, Tiziano , Branford, Susan , Cortes, Jorge , DiNardo, Courtney , Ebert, Benjamin L , Gangat, Naseema , Gianelli, Umberto , Hobbs, Gabriela S , Larson, Richard A , Löwenberg, Bob , Macintyre, Elizabeth , Malcovati, Luca , Mullighan, Charles G , Niemeyer, Charlotte Marie , Ogawa, Seishi , Passamonti, Francesco , Porkka, Kimmo , Savona, Michael R , Schmitt-Graeff, Annette , Shimamura, Akiko , Vannucchi, Alessandro M , Vyas, Paresh , Wei, Andrew H , Wierzbowska, Agnieszka , Cazzola, Mario , Döhner, Hartmut , Tzankov, Alexandar , Arber, Daniel A , Orazi, Attilio , Calvo, Katherine R. , DiNardo, Courtney D. , Facchetti, Fabio , Gianelli, Umberto , Godley, Lucy A. , Gotlib, Jason , Hobbs, Gabriela , Hoffman, Ronald , Jabbour, Elias , Kiladjian, Jean‐Jacques , Larson, Richard A. , Loh, Mignon L. , Macintyre, Elizabeth , Mullighan, Charles G. , Órfão, Alberto , Passamonti, Francesco , Pui, Ching-Hon , Rozman, Marı́a , Savona, Michael R. , Stock, Wendy , Tien, Hwei‐Fang , Vannucchi, Alessandro M.

Mayo Clinic

Blood | June 29, 2022 | Volume: 140 | Issue: 11 | Pages: 1200-1228

10.1182/blood.2022015850 | PMID 35767897 Get It

Abstract The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention
Hantel, Andrew , Kohlschmidt, Jessica, Eisfeld, Ann‐Kathrin , Stock, Wendy , Mandrekar, Sumithra J. , Larson, Richard A. , Stone, Richard M. , Lathan, Christopher S. , Byrd, John C. , Abel, Gregory A. , Byrd, John C. , Jacobson, Sawyer , Mandrekar, Sumithra J , Larson, Richard A , Stone, Richard M , Byrd, John C , Abel, Gregory A , Stock, Wendy , Byrd, John C , DeAngelo, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | June 13, 2022 | Volume: 40 | Issue: 32 | Pages: 3709-3718

10.1200/jco.22.00307 | PMID 35696629 Get It

PURPOSE Representativeness in acute leukemia clinical research is essential for achieving health equity. The National Cancer Institute's mandate for Comprehensive Cancer Centers (CCCs) to define and assume responsibility for cancer control and treatment across a geographic catchment area provides an enforceable mechanism to target and potentially remediate participatory inequities. METHODS We examined enrollee characteristics across 15 Cancer and Leukemia Group B/Alliance cooperative group adult acute leukemia clinical trials (N = 3,734) from 1998 to 2013, including participation in optional companion biobanks. We determined enrollment odds by race-ethnicity for all participants adjusted for national incidence, and for those enrolled at CCCs adjusted for catchment area incidence. We modeled biobank participation by sociodemographics using logistic regression. RESULTS Non-Hispanic (NH)-White patients were more likely to be enrolled than NH-Black, NH-Asian, or Hispanic patients (odds ratio [OR], 0.75, 0.48, and 0.44, respectively; all P < .001), but less likely than NH-Native American patients (OR, 1.91; P < .001), adjusted for national incidence. Enrollment odds were lower for NH-Black, NH-Asian, and Hispanic patients at CCCs adjusted for catchment area incidence (OR, 0.57, 0.26, and 0.32, respectively; P < .001); differences were driven by overenrollment of NH-White patients from outside self-defined catchment areas (18.1% v 12.3%; χ2 P = .01) and by CCCs with less absolute enrollee diversity (rank sum P = .03). Among all enrollees, NH-White race-ethnicity and lower neighborhood deprivation correlated with biobank participation (OR, 1.81 and 1.45, respectively; P = .01 and .03). For CCC enrollees, the correlation of race-ethnicity with biobank participation was attenuated by a measure accounting for their site's degree of enrollment disparity but not neighborhood deprivation. CONCLUSION Acute leukemia clinical research disparities are substantial and driven by structural trial enrollment barriers at CCCs. Real-time CCC access and enrollment monitoring is needed to better align research participation with local populations.
A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Kearl, Tyce , Cui, Weigo, Johnson, Bryon D. , Harrington, Alexandra M., Yi, Cecilia Ysabel Arana, Baim, Arielle , Yaghoubi, Shahriar, Murthy, Guru Subramanian Guru , Hoffmeister, Karin M. , Szabó, Anikó , Badar, Talha , DuVall, Adam , Leonard, Jessica T , Shah, Bijal , Stock, Wendy , Atallah, Ehab

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS7070-TPS7070

10.1200/jco.2022.40.16_suppl.tps7070 Get It

TPS7070 Background: Outcomes of adults with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML) have remained poor. CD38 is a transmembrane glycoprotein with several important functions including its role in immune escape of tumor cells [Chillemi A et al. Front Immunol 2017, Furano A et al. J Immunol 1990]. Several studies have demonstrated that CD38 is expressed in T-ALL and AML and is targetable with CD38 blocking agents [Naik J et al. Haematologica 2019, Bride KL et al. Blood 2018, Tembhare et al. J Immunother Cancer 2020]. XmAb18968 is a novel CD38-CD3 bi-specific T-cell engager with Fc domain modified to minimize Fcγ receptor binding and non-selective T-cell activation resulting in reduced cytokine release without compromising target cell killing. We hypothesize that targeting CD38 in relapsed/refractory T-ALL and AML would be safe and feasible using XmAb18968. Methods: This is an investigator-sponsored multi-institutional phase I study evaluating the safety and tolerability of XmAb18968. Patients aged 18 years or above with relapsed/refractory T-ALL or AML (including measurable residual disease relapse), CD38 expression ≥ 20% by flow cytometry, and adequate organ function will be eligible. Major exclusion criteria are hematopoietic cell transplantation within 6 months of enrollment, active acute graft-versus-host disease, and acute promyelocytic leukemia. The primary objective is to determine the recommended phase 2 dose (RP2D) and toxicity profile of XmAb18968. The secondary objectives include determination of response rates, duration of response, survival and pharmacokinetics. Exploratory objectives include correlation of responses with genomic profile, characterizing changes in serum cytokines and phenotypic expression of activated T-cells and leukemic cells, correlation of the phenotypic expression with changes in the transcriptome at the single-cell level, proteomics evaluation of cytokine secretion at the single-cell level and correlation of response with N-glycan profiling, quantitative site-occupancy and direct glycopeptide analysis. The study will follow 3+3 design. Dose escalation will proceed in two separate groups: Group A for subjects with T-ALL and Group B for subjects with AML. Patients will be entered sequentially to each dose level [0.8mg cohort, 1mg cohort, 1.3mg cohort, 1.5mg cohort). The observation period for dose-escalation will be 28-days. RP2D will be defined as the highest dose level at which none of the 3 treated subjects, or no more than 1 of the 6 treated subjects’ experiences a dose limiting toxicity. A minimum of 24 and a maximum of 60 patients will be enrolled. The study is being conducted at 6 sites in United States and is currently open for enrollment. Clinical trial information: NCT05038644.
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
Epstein‐Peterson, Zachary D. , Derkach, Andriy , Geyer, Susan M. , Mrózek, Krzysztof , Kohlschmidt, Jessica, Park, Jae H. , Rajeeve, Sridevi , Stein, Eytan M. , Zhang, Yanming , Iland, Harry , Campbell, Lynda J. , Powell, Bayard L., Stone, Richard M. , Tallman, Martin S. , Larson, Richard A , Derkach, Andriy , Larson, Richard A. , Poiré, Xavier , Stock, Wendy

Mayo Clinic

Blood Advances | March 29, 2022 | Volume: 6 | Issue: 11 | Pages: 3433-3439

10.1182/bloodadvances.2021006682 | PMID 35349669 Get It

AbstractFrontline arsenic trioxide (ATO)–based treatment regimens achieve high rates of long-term relapse-free survival in treating acute promyelocytic leukemia (APL) and form the current standard of care. Refining prognostic estimates for newly diagnosed patients treated with ATO-containing regimens remains important in continuing to improve outcomes and identify patients who achieve suboptimal outcomes. We performed a pooled analysis of exclusively ATO-treated patients at a single academic institution and from the ALLG APML4 and Alliance C9710 studies to determine the prognostic importance of additional cytogenetic abnormalities and/or complex karyotype. We demonstrated inferior event-free survival for patients harboring complex karyotype (hazard ratio [HR], 3.74; 95% confidence interval [CI], 1.63-8.56; P = .002), but not for patients harboring additional cytogenetic abnormalities (HR, 2.13; 95% CI, 0.78-5.82; P = .142). These data support a role for full karyotypic analysis of all patients with APL and indicate a need for novel treatment strategies to overcome the adverse effect of APL harboring complex karyotype.
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia
Kimura, Shunsuke , Montefiori, Lindsey E. , Zhao, Yaqi , Gao, Qingsong , Paietta, Elisabeth , Mead, Paul E., Gu, Zhaohui , Litzow, Mark R. , Rowe, Jacob M. , Luger, Selina M. , Schmidt, Breon , Ekert, Paul G. , Oshlack, Alicia , Grimmond, Sean M. , Rehn, Jacqueline , Breen, James , Meggendorfer, Manja , Walter, Wencke , Kern, Wolfgang , Haferlach, Torsten , Brady, Samuel W. , Zhang, Jinghui , Blombery, Piers , Montefiori, Lindsey , Zhao, Yaqi , Gao, Qingsong , Gu, Zhaohui , Litzow, Mark R. , Hunger, Stephen P , Ryland, Georgina L , Oshlack, Alicia , Grimmond, Sean M , Rehn, Jacqueline , Yeung, David , White, Deborah L , Pui, Ching-Hon , Walter, Wencke , Roberts, Kathryn G , Mullighan, Charles G , Kimura, Shunsuke , Kern, Wolfgang , Iacobucci, Ilaria , Haferlach, Claudia , Laird, Alexander , Stock, Wendy , Hunger, Stephen P. , Aldoss, Ibrahim , Jabbour, Elias , Roberts, Kathryn G. , Mullighan, Charles G.

Mayo Clinic

Blood | February 22, 2022 | Volume: 139 | Issue: 24 | Pages: 3519-3531

10.1182/blood.2022015444 | PMID 35192684 Get It

Abstract Transcriptome sequencing has identified multiple subtypes of B-progenitor acute lymphoblastic leukemia (B-ALL) of prognostic significance, but a minority of cases lack a known genetic driver. Here, we used integrated whole-genome (WGS) and -transcriptome sequencing (RNA-seq), enhancer mapping, and chromatin topology analysis to identify previously unrecognized genomic drivers in B-ALL. Newly diagnosed (n = 3221) and relapsed (n = 177) B-ALL cases with tumor RNA-seq were studied. WGS was performed to detect mutations, structural variants, and copy number alterations. Integrated analysis of histone 3 lysine 27 acetylation and chromatin looping was performed using HiChIP. We identified a subset of 17 newly diagnosed and 5 relapsed B-ALL cases with a distinct gene expression profile and 2 universal and unique genomic alterations resulting from aberrant recombination-activating gene activation: a focal deletion downstream of PAN3 at 13q12.2 resulting in CDX2 deregulation by the PAN3 enhancer and a focal deletion of exons 18-21 of UBTF at 17q21.31 resulting in a chimeric fusion, UBTF::ATXN7L3. A subset of cases also had rearrangement and increased expression of the PAX5 gene, which is otherwise uncommon in B-ALL. Patients were more commonly female and young adult with median age 35 (range,12-70 years). The immunophenotype was characterized by CD10 negativity and immunoglobulin M positivity. Among 16 patients with known clinical response, 9 (56.3%) had high-risk features including relapse (n = 4) or minimal residual disease &gt;1% at the end of remission induction (n = 5). CDX2-deregulated, UBTF::ATXN7L3 rearranged (CDX2/UBTF) B-ALL is a high-risk subtype of leukemia in young adults for which novel therapeutic approaches are required.
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia
Advani, Anjali S. , Moseley, Anna , O'Dwyer, Kristen M., Wood, Brent L. , Fang, Min, Wieduwilt, Matthew J. , Aldoss, Ibrahim, Park, Jae H., Klisovic, Rebecca B. , Baer, Maria R., Bhave, Rupali R., Harvey, Richard C., Willman, Cheryl L., Litzow, Mark R. , Stone, Richard M. , Stock, Wendy , Othus, Megan , Litzow, Mark R. , Stone, Richard M , Sharon, Elad , Erba, Harry Paul , Wieduwilt, Matthew J , Advani, Anjali S , Wood, Brent L , Moseley, Anna , O'Dwyer, Kristen M., Fang, Min, Aldoss, Ibrahim, Park, Jae H., Klisovic, Rebecca B. , Baer, Maria R., Bhave, Rupali R., Harvey, Richard C., Willman, Cheryl L.

Mayo Clinic

Journal of Clinical Oncology | February 14, 2022 | Volume: 40 | Issue: 14 | Pages: 1574-1582

10.1200/jco.21.01766 | PMID 35157496 Get It

PURPOSE Chemotherapy outcomes in older patients with Philadelphia (Ph) chromosome–negative B-acute lymphoblastic leukemia (ALL) are very poor. Here, we evaluated blinatumomab as induction and consolidation therapy followed by prednisone, vincristine, 6-mercaptopurine, and methotrexate (POMP) maintenance chemotherapy in this patient population. PATIENTS AND METHODS Patients were treated at National Clinical Trial Network sites. Eligibility criteria included age ≥ 65 years and newly diagnosed Ph chromosome–negative B-ALL. Patients received blinatumomab as induction for one-two cycles until attainment of response (complete remission (CR) and CR with incomplete count recovery). Patients then received three cycles of consolidation with blinatumomab followed by 18 months of POMP maintenance chemotherapy. Eight doses of intrathecal methotrexate were administered as central nervous system prophylaxis. RESULTS Twenty-nine eligible patients were enrolled. The median age was 75 years, and the median bone marrow blast count at diagnosis was 87%. Cytogenetic risk was poor in 10 patients (34%), and five of 14 patients (36%) tested had the Ph-like ALL gene signature. Nineteen patients (66%; 95% CI, 46 to 82) achieved CR. Kaplan-Meier 3-year disease-free survival and overall survival estimates were 37% (95% CI, 17 to 57) and 37% (95% CI, 20 to 55), respectively. CONCLUSION Blinatumomab was well tolerated and effective in the treatment of older patients with newly diagnosed Ph chromosome–negative B-ALL, including patients with poor-risk cytogenetics. The 3-year disease-free survival and overall survival results are encouraging and suggest that this approach should be further explored.
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer
Kishan, Amar U. , Steigler, Alison, Zapatero, A. , Guerrero, A., Joseph, David , Maldonado, Xavier , Wong, J.K. , Stish, Bradley J. , Dess, Robert T. , Pilar, Avinash , Wedde, Trude B. , Lilleby, Wolfgang , Fiano, Ryan , Stock, Richard G. , Demanes, D. Jeffrey, Martin, Santiago, Krauss, Daniel , Abu‐Isa, Eyad, Pisansky, Thomas M. , Choo, C. Richard, Greco, Stephen , Deville, Curtiland , McNutt, Todd , DeWeese, Theodore L. , Ross, Ashley E. , Ciezki, Jay P. , Karnes, R. Jeffrey , Tosoian, Jeffrey J. , Nickols, Nicholas G. , Bhat, Prashant , Shabsovich, David , Juarez, Jesus E. , Martin, Ting , Philipson, R., Chang, Albert J. , Kupelian, Patrick A. , Feng, Felix Y. , Reiter, Robert E. , Steinberg, Michael L. , Elashoff, David , Horwitz, Eric M. , Tendulkar, Rahul D. , Spratt, Daniel E. , Romero, Tahmineh , Davis, Brian J. , Deville, Curtiland , Spratt, Daniel E , Dess, Robert T , Ma, Ting Martin , Steigler, Allison , Denham, James William , Reddy, Chandana A. , Merrick, Gregory Stephen , Moran, Brian Joseph , Tran, Phuoc T , Martínez‐Monge, Rafael , Song, Daniel Y. , Tilki, Derya , Jiang, Tommy , Xiang, Michael H. , Rettig, Matthew B. , Berlin, Alejandro , Tward, Jonathan D. , Boutros, Paul C.

Mayo Clinic

JAMA Oncology | January 20, 2022 | Volume: 8 | Issue: 3 | Pages: e216871

10.1001/jamaoncol.2021.6871 | PMID 35050303 Get It

Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
Martin, Ting , Savjani, Ricky R. , Pollom, Erqi L., Karnes, R. Jeffrey , Wong, J.K. , Motterle, Giovanni , Tosoian, Jeffrey J. , Klein, Eric A. , Stish, Bradley J. , Dess, Robert T. , Spratt, Daniel E. , Pilar, Avinash , Levin-Epstein, Rebecca , Wedde, Trude B. , Lilleby, Wolfgang , Fiano, Ryan , Stock, Richard G. , Demanes, D. Jeffrey, Huland, Hartwig , Martin, Santiago, Krauss, Daniel , Abu‐Isa, Eyad, Schwen, Zeyad , Pisansky, Thomas M. , Choo, C. Richard, Greco, Stephen , Deville, Curtiland , McNutt, Todd , DeWeese, Theodore L. , Ross, Ashley E. , Ciezki, Jay P. , Nickols, Nicholas G. , Bhat, Prashant , Shabsovich, David , Juarez, Jesus E. , Chong, Natalie, Kupelian, Patrick A. , Reiter, Robert E. , Steinberg, Michael L. , Elashoff, David , Horwitz, Eric M. , Tendulkar, Rahul D. , Czernin, Johannes, Gafita, Andrei , Romero, Tahmineh , Calais, Jérémie , Kishan, Amar U. , Davis, Brian J. , Deville, Curtiland , Spratt, Daniel E , Dess, Robert T , Klein, Eric A , Ma, Ting Martin , Calais, Jeremie , Xiang, Michael H. , Grogan, Tristan , Trock, Bruce J , Reddy, Chandana A. , Merrick, Gregory Stephen , Moran, Brian Joseph , Tran, Phuoc T , Martínez‐Monge, Rafael , Alam, Ridwan , Song, Daniel Y. , Boutros, Paul C. , Rettig, Matthew B. , Zaorsky, Nicholas G. , Berlin, Alejandro , Tward, Jonathan D. , Tilki, Derya

Mayo Clinic

JAMA Network Open | December 13, 2021 | Volume: 4 | Issue: 12 | Pages: e2138550

10.1001/jamanetworkopen.2021.38550 | PMID 34902034 Get It

Race-Ethnic Enrollment Disparities over 15 Years of Alliance/CALGB Acute Myeloid Leukemia Clinical Trials, Biobanks, and Correlative Science Protocols
Kohlschmidt, Jessica, Eisfeld, Ann‐Kathrin , Mandrekar, Sumithra J. , Stone, Richard M. , Byrd, John C. , Abel, Gregory A. , Byrd, John C. , Hantel, Andrew , Stock, Wendy , Jacobson, Sawyer , DeAngelo, Daniel J. , Byrd, John C

Mayo Clinic

Blood | November 24, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 111-111

10.1182/blood-2021-146607 Get It

Abstract Introduction Race-ethnic disparities in clinical trial enrollment have the potential to bias findings, limit generalizability, misdirect drug development, and reduce equitable access to novel therapy. The degree to which such disparities exist within acute myeloid leukemia (AML) North American cooperative group trials, biobanks, and correlative studies remain unclear, as are the factors that influence biobank and correlative study participation among trial enrollees. In addition, the National Cancer Institute's (NCI) mandate for Comprehensive Cancer Centers (CCC) to designate catchment areas has not been explored as a mechanism through which AML enrollment disparities can be addressed. Methods We analyzed enrollment data from the 9 Alliance/CALGB AML treatment trials, 2 biobank protocols, and 2 correlative studies active from 1998-2013 and with published results. Trial enrollees could consent to biobank and/or correlative study participation. We compared participation rates of United States (US) enrollees for the mutually exclusive racial-ethnic groups of non-Hispanic (NH)-white, NH-Black, NH-Asian, NH-Native American, and Hispanic using X 2 testing, with NH-white as the comparator and reporting odds ratios (OR) and 95% confidence intervals (CI). Rates were adjusted by national incidence according to the Surveillance, Epidemiology, and End Results program and the US Census. Testing was repeated for the 55% of participants enrolled at 15 NCI CCCs recruiting ≥10 patients, where incidence was adjusted for catchment area size and demographics. Logistic regression models, clustered by trial, were performed to assess the following predictors for biobank and correlative study participation among trial enrollees: race-ethnicity (NH-white vs non-white), site type (CCC status), age (10-year increments), sex, neighborhood urbanity (urban vs rural) and poverty (&lt;20% vs ≥20% below poverty line) by zip code, and distance from site (10-mile increments). Results There were 3041 trial enrollees at US sites; participant characteristics and demographics by race-ethnicity are shown in Table 1. 93.9% of patients participated in a biobanking study and 60.0% in a correlative study. National incidence adjusted enrollment odds by race-ethnicity are shown in the Figure (top); NH-Black, NH-Asian, and Hispanic persons were enrolled at significantly lower rates than NH-whites; NH-Native American enrollment was significantly higher. Enrollment odds were even lower for NH-Black, NH-Asian, and Hispanic enrollees at CCC sites when adjusted by catchment area incidence (Figure; bottom). Among trial enrollees, there were no univariable predictors of biobank participation, however, male sex (OR 1.12; 95% CI 1.01, 1.37; p=0.04) and NH-white race-ethnicity (OR 1.33; 95% CI 1.12,1.57; p&lt;0.001) were associated with correlative study participation. Multivariable models of correlative study participation, with predictors selected based on univariable significance, are shown in Table 2 for all trial enrollees and when restricted to biobank enrollees; in both cases, NH-white race predicted participation. Conclusions Across 15 years of AML cooperative group studies, there were several enrollment disparities by race-ethnicity, which were more pronounced at CCC sites. Over 90% of trial enrollees participated in biobanking, with no race-ethnic differences seen. However, correlative study participation among trial enrollees was higher for NH-whites. Taken together, these data suggest that efforts should focus on increasing trial and correlative study participant diversity-but not biobanking-within NCI-designated CCC catchment areas. Reasonable next steps include identifying key structural, provider, and patient-based barriers to trial and correlative study participation at CCC sites and developing inclusive, multilevel interventions to address them. Figure 1 Figure 1. Disclosures Eisfeld: Karyopharm (spouse): Current Employment. Stock: Pfizer: Consultancy, Honoraria, Research Funding; amgen: Honoraria; agios: Honoraria; jazz: Honoraria; kura: Honoraria; kite: Honoraria; morphosys: Honoraria; servier: Honoraria; syndax: Consultancy, Honoraria; Pluristeem: Consultancy, Honoraria. Stone: AbbVie Inc, Actinium Pharmaceuticals Inc, Aprea Therapeutics, BerGenBio ASA, ElevateBio, Foghorn Therapeutics, GEMoaB, GlaxoSmithKline, Innate Pharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Takeda Oncology: Other: Advisory Committee; Agios Pharmaceuticals Inc, Novartis;: Research Funding; ACI Clinical, Syntrix Pharmaceuticals, Takeda Oncology: Other: Data Safety & Monitoring. DeAngelo: Abbvie: Research Funding; Blueprint: Research Funding; Takeda: Consultancy; Autolus: Consultancy; Forty-Seven: Consultancy; Incyte: Consultancy; Jazz: Consultancy; Novartis: Consultancy, Research Funding; Pfizer: Consultancy; Servier: Consultancy; Amgen: Consultancy; Agios: Consultancy; Glycomimetrics: Research Funding. Byrd: Newave: Membership on an entity's Board of Directors or advisory committees; Vincerx Pharmaceuticals: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Novartis, Trillium, Astellas, AstraZeneca, Pharmacyclics, Syndax: Consultancy, Honoraria.